Verapamil: Full spectrum calcium channel blocking agent: An overview
- 1 January 1984
- journal article
- research article
- Published by Wiley in Medicinal Research Reviews
- Vol. 4 (1), 87-109
- https://doi.org/10.1002/med.2610040106
Abstract
Oral verapamil approved for use in all forms of angina, with its additional heart rate-controlling properties has undergone extensive clinical investigation and use since its initial development and has been demonstrated to be safe, well-tolerated and effective over a broad range of cardiovascular disorders. Further potential therapeutic indications for verapamil use remain to be assessed. Additional research with this exciting drug is ongoing.Keywords
This publication has 69 references indexed in Scilit:
- Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study.Circulation, 1982
- Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.Circulation, 1982
- The effects of intravenous verapamil on hemodynamic status of patients with coronary artery disease receiving propranolol.Circulation, 1982
- Verapamil versus placebo in relieving stable angina pectoris.Circulation, 1982
- Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.Circulation, 1981
- Coronary artery spasm during exercise: treatment with verapamil.Circulation, 1981
- A Controlled Trial of Verapamil for Prinzmetal's Variant AnginaNew England Journal of Medicine, 1981
- Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.Circulation, 1979
- Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects.Circulation, 1979
- Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction.Circulation, 1978